Seeking Alpha

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading ...
Investing

Recursion licenses HealthVerity real-world data for trials

PHILADELPHIA - Recursion (NASDAQ: RXRX), a clinical stage TechBio company with a market capitalization of $2.27 billion, has entered into a licensing agreement with HealthVerity to utilize its ...
Seeking Alpha

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition ...

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two significant ...
Investing

Recursion releases OpenPhenom-S/16 for microscopy data

SALT LAKE CITY - Recursion, a clinical stage TechBio company listed on NASDAQ:RXRX, introduced a new foundation model named OpenPhenom-S/16, now accessible in the Vertex (NASDAQ:VRTX) AI Model Garden ...
GEN

Drugs, Dollars, and Data: Recursion Eyes Cost Savings from AI Drug Discovery

Announcing an artificial intelligence (AI) drug discovery partnership with Nvidia earlier this month, Recursion co-founder and CEO Chris Gibson, PhD, spoke as much about dollars as he did about drugs ...
GEN

StockWatch: Recursion Slides on Data Update as New CEO Named

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...